How Does Idebenone Treat LHON? How Long Should I Take It?

Idebenone (often sold under the brand name Raxone) is thought to treat Leber hereditary optic neuropathy (LHON) by acting as an “electron carrier” that can bypass impaired mitochondrial machinery, potentially helping cells restore energy production ^[1][2]. When determining how long a patient must take it, early observational studies initially suggested a duration of 1.5 years (18 months) ^[3]. However, recent international consensus guidelines now recommend that treatment should be initiated early and continued for at least 24 months (2 years), or until a patient’s visual improvement reaches a confirmed plateau ^[4].

The Proposed Mechanism of Action

To understand how Idebenone is intended to help, it is useful to know the cellular mechanics of LHON. The condition is caused by a genetic mutation that impairs a specific structure inside the mitochondria (the cell’s “powerhouses”) known as Complex I ^[5]. When Complex I is defective, two major issues occur:

1. The cells cannot produce enough ATP, which is the vital energy currency of the cell ^[5].
2. The cells produce an excess of reactive oxygen species (harmful free radicals), leading to oxidative stress ^[1].

This combination of low energy and high stress damages the retinal ganglion cells, whose axons gather together to form the optic nerve ^[1][5].

Idebenone is a synthetic compound similar to Coenzyme Q10. Once inside the cell, it is proposed to pick up electrons and shuttle them directly to Complex III, effectively bypassing the defective Complex I ^[1][2]. By bridging this gap, Idebenone may help restart the electron transport chain and restore the cell’s ability to produce ATP ^[1][6]. Furthermore, Idebenone has antioxidant properties that may help clear away harmful reactive oxygen species, potentially protecting the optic nerve from ongoing damage ^[6][5].

For the drug to work in this way, a specific cellular enzyme (NQO1) is thought to first reduce or “activate” the Idebenone ^[7]. While individual differences in this enzyme might help explain why some patients respond better than others, routine clinical testing for NQO1 is not currently standard practice for predicting treatment success ^[2]. It is also important to note that Idebenone is a treatment, not a guaranteed cure, and it does not repair the underlying genetic mutation.

Guidelines for Treatment Duration

Research and international consensus guidelines emphasize that Idebenone generally works best when maintained consistently over a long period ^[8][4].

• The Shift to at Least 24 Months: While older reports suggested a 1.5-year target ^[3], more recent large-scale observational studies and consensus reviews have observed that the proportion of patients who recover—and the magnitude of their visual gains—often increases the longer they remain on the medication ^[9]. Because of this, guidelines advise treating for a minimum of 24 months ^[4]. It should be noted that long-term data is observational, and individual responses vary, as spontaneous visual recovery can also occur naturally in LHON ^[10][9].
• Treating Until a Plateau: Visual recovery can sometimes continue well beyond the two-year mark, with some real-world patient cohorts showing peak improvements around 27 months ^[11]. Therefore, specialists generally recommend continuing treatment until visual improvement has clearly reached a plateau ^[4].

A plateau means your vision has remained stable without further measurable gains across multiple visits. This is not determined by a single standard eye chart test; your neuro-ophthalmologist will use repeated assessments that may include visual fields, color and contrast testing, and imaging like OCT (Optical Coherence Tomography) to accurately measure your progress ^[9]. You should never stop or extend your treatment based solely on your own day-to-day impressions of your vision; always make these decisions in close consultation with your specialist.